Literature DB >> 12452827

Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes.

T Matsuoka1, Y Okamoto, Z Matsuzaki, S Endo, E Ito, H Tsutsumi, R A Williamson, H Sakurai, D R Burton, I Saito.   

Abstract

The characteristics of the immunity induced by viral antigens or conferred by antiviral antibody via different routes of administration were evaluated comparatively. C57BL/6 mice were immunized via intranasal, intradermal or enteric routes with a live recombinant vaccinia virus expressing the respiratory syncytial virus (RSV) F glycoprotein (F.rVV) or RSV, and then challenged intranasally with RSV. Inhibition of RSV replication was observed in the lungs of all the mice; however, only intranasal immunization hindered virus replication in the nose. Lung inflammation, characterized by infiltration of neutrophils and of mononuclear cells was strongest in the intradermally immunized mice, but was observed in all F.rVV immunized mice to various degrees. Intranasal administration of a potently neutralizing human anti-RSV antibody Fab fragment to infected mice inhibited RSV replication in the nose and, when combined with intraperitoneal administration, protected both the lung and the nose in the absence of deleterious lung pathology. These data suggest that intranasal immunization with F.rVV reduces RSV replication in the respiratory tract, but still induces pathological lung inflammation, even though this is milder than that observed following intradermal immunization. Local neutralizing antibody is indispensable for protection in the nose.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452827      PMCID: PMC1906556          DOI: 10.1046/j.1365-2249.2002.02003.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Monoclonal antibodies to the large glycoproteins of respiratory syncytial virus: possible evidence for several functional antigenic sites.

Authors:  H Tsutsumi; T D Flanagan; P L Ogra
Journal:  J Gen Virol       Date:  1987-08       Impact factor: 3.891

2.  Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues.

Authors:  M R McDermott; J Bienenstock
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

3.  Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system.

Authors:  P Weisz-Carrington; M E Roux; M McWilliams; J M PHILLIPS-Quagliata; M E Lamm
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

Review 4.  Induction of the mucosal immune response.

Authors:  M W Russell; J Mestecky
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus.

Authors:  T Kumagai; D T Wong; P L Ogra
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

6.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

8.  Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.

Authors:  F Y Liew; S M Russell; G Appleyard; C M Brand; J Beale
Journal:  Eur J Immunol       Date:  1984-04       Impact factor: 5.532

9.  Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial.

Authors:  R B Belshe; L P Van Voris; M A Mufson
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

10.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus.

Authors:  M J Cannon; P J Openshaw; B A Askonas
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  6 in total

1.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.

Authors:  Sherry L Kurtz; Oded Foreman; Catharine M Bosio; Miriam R Anver; Karen L Elkins
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

3.  Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Authors:  Howard L Kaufman; Gail Deraffele; Josephine Mitcham; Dorota Moroziewicz; Seth M Cohen; Karl S Hurst-Wicker; Ken Cheung; David S Lee; Joseph Divito; Magalese Voulo; Julie Donovan; Kate Dolan; Kelledy Manson; Dennis Panicali; Ena Wang; Heidi Hörig; Francesco M Marincola
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

4.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

Review 5.  Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Authors:  Patricio L Acosta; Mauricio T Caballero; Fernando P Polack
Journal:  Clin Vaccine Immunol       Date:  2015-12-16

6.  Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.

Authors:  Joseph R Francica; Barbara J Flynn; Kathryn E Foulds; Amy T Noe; Anne P Werner; Ian N Moore; Matthew Gagne; Timothy S Johnston; Courtney Tucker; Rachel L Davis; Britta Flach; Sarah O'Connell; Shayne F Andrew; Evan Lamb; Dillon R Flebbe; Saule T Nurmukhambetova; Mitzi M Donaldson; John-Paul M Todd; Alex Lee Zhu; Caroline Atyeo; Stephanie Fischinger; Matthew J Gorman; Sally Shin; Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Seyhan Boyoglu-Barnum; Renee Van De Wetering; Alida Tylor; Elizabeth McCarthy; Valerie Lecouturier; Sophie Ruiz; Catherine Berry; Timothy Tibbitts; Hanne Andersen; Anthony Cook; Alan Dodson; Laurent Pessaint; Alex Van Ry; Marguerite Koutsoukos; Cindy Gutzeit; I-Ting Teng; Tongqing Zhou; Dapeng Li; Barton F Haynes; Peter D Kwong; Adrian McDermott; Mark G Lewis; Tong Ming Fu; Roman Chicz; Robbert van der Most; Kizzmekia S Corbett; Mehul S Suthar; Galit Alter; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Barney S Graham; Danilo Casimiro; Robert A Seder
Journal:  Sci Transl Med       Date:  2021-07-27       Impact factor: 19.319

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.